NCT02676349 2026-03-27
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
Institut de Cancérologie de Lorraine
Phase 2 Completed
Clinical Trials
9 trialsNCT00089024 2023-09-29
Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
University of Nebraska
Phase 2 Completed
NCT00049348 2023-06-15
Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT05679583 2023-01-11
Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer
Yonsei University
Phase 2 Recruiting
NCT00010166 2021-09-09
Gemcitabine and Radiation Therapy in Treating Patients With Cancer of the Pancreas
Wake Forest University Health Sciences
Phase 2 Completed
NCT00536874 2017-03-16
Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00253526 2015-04-28
Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT00335543 2013-08-12
Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00425841 2012-12-12
Stereotactic Radiation Therapy and Combination Chemotherapy in Treating Patients Undergoing Surgery for Locally Advanced Pancreatic Cancer
Technical University of Munich
Phase 2 Completed